Live from BIO 2024: Advanced therapies - What's next?

What’s the current state and future of advanced therapies?
In this discussion, we focused on the broader industry landscape, including the convergence of scientific modalities and the significant progress in advanced therapies.
Emmanuel Abate, President of Genomic Medicine at Cytiva, and Nathaniel Wang, CEO and Co-Founder of Replicate Bioscience join us to express their optimism about future innovations in the space.
Yes, there are opportunities but there are also hurdles. Both speakers stress the importance of accessibility and cost reduction for these advanced therapies to reach a broader patient base. They also address the potential impact of AI in the industry, emphasizing the need for careful integration and transparency to build public trust.
To learn more about what’s next for advanced therapies here: cytiva.link/4fs2i.